Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 06, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
September 26, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
September 10, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 06, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial
August 29, 2022 13:58 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting
May 18, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 07:00 ET
|
Cabaletta Bio
– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 – – Multiple...
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May
May 02, 2022 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...